Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
![Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press](https://content.iospress.com/media/kca/2019/3-2/kca-3-2-kca190059/kca-3-kca190059-g003.jpg?width=755)
Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press
![Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner, Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,](https://journals.sagepub.com/cms/10.1177/1758835918788500/asset/images/large/10.1177_1758835918788500-fig4.jpeg)
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram](https://www.researchgate.net/publication/26296813/figure/fig1/AS:601645264158732@1520454817617/Comparison-of-progression-free-survival-A-or-overall-survival-B-after-the-initiation.png)
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
![Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-14-18/MediaObjects/12885_2013_Article_4261_Fig1_HTML.jpg)
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-gr3.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials | Haematologica
![Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram](https://www.researchgate.net/publication/233746224/figure/fig2/AS:601587995136000@1520441163001/Progression-free-survival-and-overall-survival-curves-for-all-patients-with-different.png)
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure1-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure2-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram](https://www.researchgate.net/publication/306551418/figure/fig3/AS:567236567855104@1512251144196/Progression-free-survival-PFS-A-and-overall-survival-OS-B-based-on-disease-free.png)
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
How do doctors interpret differences between overall survival and progression free survival? - Quora
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab](https://www.mdpi.com/cancers/cancers-12-03021/article_deploy/html/images/cancers-12-03021-g001-550.jpg)
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
![Progression free survival and overall survival in patients treated with... | Download Scientific Diagram Progression free survival and overall survival in patients treated with... | Download Scientific Diagram](https://www.researchgate.net/publication/320272594/figure/fig3/AS:547183110098944@1507470027498/Progression-free-survival-and-overall-survival-in-patients-treated-with-nivolumab-based.png)
Progression free survival and overall survival in patients treated with... | Download Scientific Diagram
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fbjc.2016.83/MediaObjects/41416_2016_Article_BFbjc201683_Fig2_HTML.jpg)
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer
![Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download](https://slideplayer.com/16198544/95/images/slide_1.jpg)
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)